Capricor Therapeutics, a biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics, and Lonza, entered an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.   CAP-1002 completed the Phase 2 clinical trial and has been granted orphan drug designation by the FDA for the trea...